
    
      This multicenter study is open with respect to the treatment allocation, but double-blind
      with respect to the Hib-MenC-TT lots (3 lots). The study will be conducted in two stages.
      Primary vaccination phase: 3 doses Hib-MenC-TT with Infanrix™-IPV or for the control group a
      licensed Men-C vaccine with Pediacel™ at 2, 3, 4 months of age; Booster/persistence phase: 1
      dose Hib-MenC with Priorix™. 4 blood samples of 3.5ml (5ml for the UK subset) are collected
      (Study Months 0 & 3, prior to & 42 days after the booster).
    
  